Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis

Table 2 Summary characteristics of studies with 100% efficacy of artemisinin combination therapy at day 28 among P. falciparum patients

Author, publication year	Country	Setting	Drug	Age	n	N	p
Davlantes 2018 [25]	Angola	Benguela (stable mesoendemic transmission)	DP	< 12 years	85	85	100
		Benguela (stable mesoendemic transmission)	ASAQ	< 12 years	90	90	100
		LundaSul-hyperendemic transmission)	DP	< 5 years	89	89	100
Ojurongbe 2013 [34]	Nigeria	University hospital, transmission throughout the year	AL	6 m to 12 years	89	89	100
Ojurongbe 2013 [34]	Nigeria	University hospital, transmission throughout the year	ASAQ		71	71	100
Plucinski 2017 [35]	Angola	Benguela (stable mesoendemic transmission)	ASAQ	6 m to 12 years	66	66	100
		LundaSul-hyperendemic transmission)	DP		76	76	100
		LundaSul-hyperendemic transmission)	ASAQ		56	56	100
Ramharter 2008 [37]	Gabon	Hospital. transmitted perennially	AP (tablet)	2–14 years	13	13	100
Ramharter 2008 [37]	Gabon	Hospital. transmitted perennially	AP (Granule)	2–14 years	14	14	100
Sawa 2013 [38]	Kenya	moderate transmission intensity	DP	6 m to 10 years	137	137	100
Shayo 2014 [39]	Tanzania	Health Center. Moderate to high transmission	DP	6 months to 10 years	40	40	100
Shayo 2014 [39]	Tanzania		AL	6 m to 10 years	21	21	100
Mens 2008 [31]	Kenya	primary health centers, transmission low and predominantly seasonal	DP	6 m to 12 years	67	67	100
Mens 2008 [31]	Kenya		AL	6 m to 12 years	66	66	100
Kabanywanyi 2007 [28]	Tanzania	health facilities, perennial with seasonal peaks	AL	6 to 59 months	86	86	100
Dorkenoo 2012 [27]	Togo	Urban, university and childs hospital, endemic or seasonal transmission	AL	6 to 59 months	538	538	100

ISSN: 1471-2334